Equities

TG Therapeutics Inc

TG Therapeutics Inc

Actions
  • Price (CHF)15.64
  • Today's Change0.00 / 0.00%
  • Shares traded40.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Dec 15 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments218162315
Total Receivables, Net5101.39
Total Inventory40----
Prepaid expenses4.184.2412
Other current assets, total5.342.362.88
Total current assets318168331
Property, plant & equipment, net9.561111
Goodwill, net0.800.800.80
Intangibles, net------
Long term investments01236
Note receivable - long term------
Other long term assets------
Total assets330194380
LIABILITIES
Accounts payable------
Accrued expenses141012
Notes payable/short-term debt000
Current portion long-term debt/capital leases--00.98
Other current liabilities, total1.631.171.51
Total current liabilities545365
Total long term debt1007167
Total debt1007168
Deferred income tax------
Minority interest------
Other liabilities, total151110
Total liabilities169135142
SHAREHOLDERS EQUITY
Common stock0.150.150.14
Additional paid-in capital1,6751,5861,566
Retained earnings (accumulated deficit)(1514)(1527)(1329)
Treasury stock - common(0.23)(0.23)(0.23)
Unrealized gain (loss)------
Other equity, total------
Total equity16159237
Total liabilities & shareholders' equity330194380
Total common shares outstanding151146143
Treasury shares - common primary issue0.040.040.04
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.